Components of the metabolic syndrome - Risk factors for the development of benign prostatic hyperplasia

Prostate Cancer and Prostatic Diseases

Volumn 1, Issue 3, 1998, Pages 157-162

  Hammarsten, J ^a   Hogstedt B ^b   Holthuis, N ^c   Mellstrom D ^d  

^a VARBERG HOSPITAL   (Sweden)

^b Department of Occupational Medicine ^*  (Sweden)

^c HALMSTAD HOSPITAL   (Sweden)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Benign prostatic hyperplasia; Dyslipidemia; Hyperinsulinemia; Hypertension; Metabolic syndrome; Non insulin dependent diabetes mellitus; Obesity

Indexed keywords

EID: 0001154983     PISSN: 13657852     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500221     Document Type: Article

References (33)

1. Guess HA. Benign prostatic hyperplasia: antecedents and natural history. Epidemiol Rev 1992; 14: 131-153.
2. Partin AW et al. Influence of age and endocrine factors on the volume of benign prostatic hyperplasia. J Urol 1991; 145: 405-409.
3. Horton R et al. Altered blood androgens in elderly men with prostate hyperplasia. J Clin Endocrinol Metab 1975; 41: 793-796.
4. Vermeulen A, De Sy W. Androgens in patients with benign prostatic hyperplasia before and after prostatectomy. J Clin Endocrinol Metab. 1976; 43: 1250-1254.
5. Ishimaru T, Pages L, Horton R. Altered metabolism of androgens in elderly men with benign prostatic hyperplasia. J Clin Endocrinol Metab 1977; 45: 695-701.
6. Hammond GL, Kontturi M, Vihko P, Vihko R. Serum steroids in normal males and patients with prostatic diseases. Clin Endocrinol 1978; 9: 113-121.
7. Bartsch W, Becker H, Pinkenburg FA, Krieg M. Hormone blood levels and their inter-relationships in normal men and men with benign prostatic hyperplasia (BPH). Acta Endocrinol 1979; 90: 727-736.
8. Lukkarinen O. Total and SHBG-bound testosterone and 5 alpha-dihydro testosterone serum concentrations in normal elderly men and patients with benign prostatic hypertrophy before and after removal of the adenoma. Br J Urol 1980; 52: 377-380.
9. Drafta D et al. Plasma steroids in benign prostatic hypertrophy and carcinoma of the prostate. J Steroid Biochem 1982; 17: 689-693.
10. Brochu M, Belanger A. Comparative study of plasma steroid and steroid glucoronide levels in normal men and in men with benign prostatic hyperplasia. Prostate 1987; 11: 33-40.
11. Bourke JB, Griffin JP. Hypertension, diabetes mellitus, and blood groups in benign prostatic hypertrophy. Br J Urol 1966; 38: 18-23.
12. Daniell HW. Larger prostatic adenomas in obese men with no associated increase in obstructive uropathy. J Urol 1993; 149: 315-317.
13. Sidney S et al. Risk factors for surgically treated benign prostatic hyperplasia in a prepaid health care plan. Urology 1991; 38(1): 13-19.
14. Glynn RJ, Campion EW, Bouchard GR, Silbert JE. The development of benign prostatic hyperplasia among volunteers in the Normative Aging Study. Amer J Epidemiol 1985; 121: 78-90.
15. Castro JE, Griffiths HJL, Shackman R. Significance of signs and symptoms in benign prostatic hypertrophy. Br Med J 1969; 2: 598-601.
16. Epstein RS, Lydick E, deLabry L, Vokonas PS. Age-related differences in risk factors for prostatectomy for benign prostatic hyperplasia: The VA Normative Aging Study. Urology 1991; 38(1): 13-19.
17. Arrighi HM, Guess HA, Metter EJ, Fozard JL. Symptoms and signs of prostatism as risk factors for prostatectomy. Prostate 1990; 16: 253-261.
18. Littrup PJ, Williams CR, Egglin TK, Kane RA. Determination of prostate volume with transrectal US for screening - Part II. Accuracy of in vitro and in vivo techniques. Radiology 1991; 179: 49-53.
19. Terris MK, Stamey TA. Determination of prostate volume by transrectal ultrasound. J Urol 1991; 145: 984-987.
20. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14: 173-194.
21. Reavan GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.
22. Rett K, Wicklmayr M, Mehnert H. New aspects of insulin resistance in hypertension. Eur Heart J 1994; 15(C): 78-81.
23. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984; 132: 474-479.
24. Girman CJ et al. Natural history of prostatism: Relationship among symptoms, prostate volume and peak urinary flow rate. J Urol 1995; 153: 1510-1515.
25. Krotkiewski M. Role of muscle capillarization and morphology in the development of insulin resistance and metabolic syndrome. Presse Med 1994; 23: 1353-1356.
26. McNeal J. Pathology of benign prostatic hyperplasia. Insight into etiology. Urol Clin North Am 1990; 17: 477-486.
27. Landsberg L. Diet, obesity and hypertension: an hypothesis involving insulin, the sympathetic nervous system, and adaptive thermogenesis. Q J Med 1986; 236: 1081-1090.
28. Berne C, Fagius J, Niklasson F. Sympathetic response to oral carbohydrate administration. Evidence from microelectrode nerve recordings. J Clin Invest 1989; 84: 1403-1409.
29. Berne C, Pollare T, Fagius J. The sympathetic outflow in vasoconstrictor nerve fascicles to muscle is increased during euglycaemic hyperinsulinaemia. Diabetologia 1989; 32: 465A.
30. Shieh S-M et al. Glucose, insulin, and lipid metabolism in doxazosin-treated patients with hypertension. Am J Hypertens 1992; 5: 827-831.
31. Pollare T, Lithell H, Selinus I, Berne C. Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension. Diabetologia 1988; 31: 415-420.
32. Swislocki ALM et al. Effect of prozasin treatment on carbohydrate and lipoprotein metabolism in patients with hypertension. Am J Med 1989; 86: 14-18.
33. Andersson P-E, Johansson J, Berne C, Lithell H. Effects of selective alpha1 and beta1-adrenoreceptor blockade on lipoprotein and carbohydrate metabolism in hypertensive subjects with special emphasis on insulin sensitivity. J Hum Hypertens 1994; 8: 219-226.